Flow Cytometry Global Market Report 2024

The flow cytometry market size has grown strongly in recent years. It will grow from $6.24 billion in 2023 to $6.84 billion in 2024 at a compound annual growth rate (CAGR) of 9.5%. The historic growth in the field of flow cytometry can be attributed to its diverse applications, including immunophenotyping, cancer research, hematology and blood cell analysis, clinical diagnostics, and drug discovery and development. Flow cytometry has played a crucial role in advancing these areas by providing powerful tools to analyze and characterize cells and particles with high precision, making it invaluable in research, diagnostics, and therapeutic development.

The flow cytometry market size is expected to see rapid growth in the next few years. It will grow to $10.22 billion in 2028 at a compound annual growth rate (CAGR) of 10.6%.

The forecasted growth in the field of flow cytometry can be attributed to various factors, including the increasing use of single-cell analysis in research and diagnostics, advancements in immunotherapy and CAR-T cell development, the rising importance of flow cytometry in infectious disease research, the discovery of new biomarkers, and the growing demand for point-of-care testing (POCT) solutions. Additionally, major trends in the forecast period encompass multicolor analysis, automation and robotics, imaging flow cytometry, data analysis and informatics, and innovations in sample preparation techniques, which are expected to enhance the capabilities and applications of flow cytometry.

Flow cytometry employs different technologies, including cell-based and bead-based methods, with applications spanning oncology, drug discovery, disease diagnosis, stem cell therapy, organ transplantation, and hematology. This technology serves a diverse range of end-users, including hospitals and clinics, academic and research institutions, pharmaceutical and biotechnology companies, as well as other sectors, to advance scientific research and healthcare practices.

The flow cytometry market research report is one of a series of new reports that provides flow cytometry market statistics, including flow cytometry industry global market size, regional shares, competitors with a flow cytometry market share, detailed flow cytometry market segments, market trends and opportunities, and any further data you may need to thrive in the flow cytometry industry. This flow cytometry market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The increasing global prevalence of HIV cases serves as a significant driver for the flow cytometry market. Flow cytometry plays a pivotal role in HIV diagnosis by utilizing light scattering to identify specific cell clusters known as CDs (clusters of differentiation), with CD4 being the marker for HIV virus cells. By quantifying the CD4 count in a medium, flow cytometry aids in HIV diagnosis. As the worldwide HIV population continues to rise, there is a growing demand for diagnostic techniques like flow cytometry.

The growth of the flow cytometry market is further attributed to the increasing number of drug launches. These launches pertain to the introduction of new pharmaceutical products into the market, involving extensive research, development, regulatory approvals, and distribution. Flow cytometry plays a vital role in drug launches by assessing cellular responses, drug effectiveness, and toxicity, ensuring the safe introduction of medications. It enables precise characterizations necessary for regulatory approvals and post-launch monitoring. For instance, a report by IQVIA in December 2021 predicts that around 300 new drugs are expected to be introduced by 2026, representing a significant increase compared to the past decade. These new drug launches, particularly focusing on specialty, niche, and orphan drugs, are projected to lead to a substantial rise in healthcare expenditures, estimated at approximately $196 billion.

The availability of more cost-effective and efficient substitutes poses a significant challenge to the flow cytometry market. These substitutes include ELISA (enzyme-linked immunosorbent assay) and radioimmunoassay. While all three methods aid in HIV diagnosis by identifying problematic cells within a cell group, ELISA and radioimmunoassay are more cost-effective and straightforward than flow cytometry. ELISA employs reagents with color changes to detect problematic cells, while radioimmunoassay uses specific radioactive markers for cell detection. Both ELISA and radioimmunoassay can be implemented with readily available, traditional laboratory equipment and reagents, offering a higher throughput rate. In contrast, flow cytometry involves substantial setup costs, data interpretation expenses, and offers a lower throughput rate.

An emerging trend in the flow cytometry market is the adoption of high-throughput flow cytometry. This approach leverages the rapid processing of cell parameters and the ability to simultaneously analyze diverse cell groups. Traditional cytometry methods tend to be slow, especially when dealing with multiple cells within a short timeframe. High-throughput flow cytometry, including techniques like fluorescence-activated cell sorting (FACS), allows for the allocation of fluorescent markers to multiple cells, enabling the swift analysis of their parameters. Companies such as AstraZeneca and Novartis are providing high-throughput flow cytometry solutions.

Advancements in flow cytometry devices driven by regulatory compliance and safety measures the US FDA has established regulations within its Code of Federal Regulations (CFR) for flow cytometry devices, particularly the automated differential cell counter (ADCC). ADCC devices are used in the analysis of blood cells, primarily for the detection of abnormal blood cells and low blood cell counts. These devices fall under the category of class 2 special controls, which outline specific requirements for accurate and precise result reporting, statistical linearity conditions for graph-based cytometry results, and the types of specimens to be used. Flow cytometry device manufacturers must adhere to these guidelines, addressing health risks associated with ADCC devices. Consequently, these regulations play a crucial role in monitoring companies involved in manufacturing ADCC and other flow cytometry devices.

In February 2022, KCAS Bioanalytical and Biomarker Services, a US-based development service provider compliant with GLP and GCP standards, acquired FlowMetric LLC for an undisclosed amount. This acquisition is expected to bolster KCAS's capabilities in the field of analytical testing. FlowMetric is a US-based provider of flow cytometry and cellular assay services.

Major companies operating in the flow cytometry market include Beckman Coulter Inc., Agilent Technologies Inc., Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Luminex Corporation, Miltenyi Biotec Ltd., Becton Dickinson and Company, Sysmex Corporation, Merck KGaA, Danaher Corporation, Apogee Flow Systems Ltd., Stratedigm Inc., General Electric Company, EMD Millipore Corporation, Affymetrix Inc., Biomérieux SA, Cytonome St LLC, Enzo Life Sciences Inc., Sony Biotechnology Inc., Life Technologies Corporation, ACEA Biosciences Inc., Takara Bio Inc., Union Biometrica Inc., Cytek Biosciences Inc., Nexcelom Bioscience LLC, Verity Software House Inc., Spectral Cytometry Systems GmbH, InstruNor AS

North America was the largest region in the flow cytometry market in 2023. Western Europe was the second largest region in the flow cytometry market analysis. The regions covered in the flow cytometry market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the flow cytometry market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The flow cytometry market includes revenue earned by cytometry systems, panel builders, and instruments. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.